Modulation of neuronal survival factor MEF2 by kinases in Parkinson's disease

Frontiers in Physiology

Volumn 3 MAY, Issue , 2012, Pages

  Yin, Yue ^a,b   She, Hua ^b   Li, Wenming ^b   Yang, Qian ^b   Guo, Shuzhong ^a   Mao, Zixu ^b  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Autophagy; Kinase; MEF2; Mitochondria; Neurodegeneration; PD

Indexed keywords

EID: 84866343966     PISSN: None     EISSN: 1664042X     Source Type: Journal    
DOI: 10.3389/fphys.2012.00171     Document Type: Review

References (148)

1. Ahuja, H. S., Zhu, Y., and Zakeri, Z. (1997). Association of cyclin-dependent kinase 5 and its activator p35 with apoptotic cell death. Dev. Genet. 21, 258-267.
2. Alam, Z. I., Daniel, S. E., Lees, A. J., Marsden, D. C., Jenner, P., and Halliwell, B. (1997a). A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. J. Neurochem. 69, 1326-1329.
3. Alam, Z. I., Jenner, A., Daniel, S. E., Lees, A. J., Cairns, N., Mars-den, C. D., Jenner, P., and Halli-well, B. (1997b). Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J. Neurochem. 69, 1196-1203.
4. Alegre-Abarrategui, J., Christian, H., Lufino, M. M., Mutihac, R., Venda, L. L., Ansorge, O., and Wade-Martins,R. (2009). LRRK2 regulates autophagic activity and localizes to specific membranemicrodomains in a novel human genomic reporter cellular model. Hum. Mol. Genet. 18, 4022-4034.
5. Amo, T., Sato, S., Saiki, S., Wolf, A. M., Toyomizu, M., Gautier, C. A., Shen, J., Ohta, S., and Hattori, N. (2011). Mitochondrial membrane potential decrease caused by loss of PINK1 is not due to proton leak, but to respiratory chain defects. Neurobiol. Dis. 41, 111-118.
6. Bijur, G. N., and Jope, R. S. (2001). Proapoptotic stimuli induce nuclear accumulation of glycogen synthase kinase-3 beta. J. Biol. Chem. 276, 37436-37442.
7. Braak, H., Del Tredici, K., Rub, U., De Vos, R. A., Jansen Steur, E. N., and Braak, E. (2003). Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24, 197-211.
8. Brown, E. J., Albers, M. W., Shin, T. B., Ichikawa, K., Keith, C. T., Lane, W. S., and Schreiber, S. L. (1994). A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 369, 756-758.
9. Buschbeck, M., and Ullrich, A. (2005). The unique C-terminal tail of the mitogen-activated protein kinase ERK5 regulates its activation and nuclear shuttling. J. Biol. Chem. 280, 2659-2667.
10. Cavanaugh, J. E., Ham, J., Hetman, M., Poser, S., Yan, C., and Xia, Z. (2001). Differential regulation of mitogen-activated protein kinases ERK1/2 and ERK5 by neurotrophins, neuronal activity, and cAMP in neurons. J. Neurosci. 21, 434-443.
11. Chae, T., Kwon, Y. T., Bronson, R., Dikkes, P., Li, E., and Tsai, L. H. (1997). Mice lacking p35, a neu-ronal specific activator of Cdk5, display cortical lamination defects, seizures, and adult lethality. Neuron 18, 29-42.
12. Chen, J., Zheng, X. F., Brown, E. J., and Schreiber, S. L. (1995). Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue. Proc. Natl. Acad. Sci. U.S.A. 92, 4947-4951.
13. Chiu, M. I., Katz, H., and Berlin, V. (1994). RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex. Proc. Natl. Acad. Sci. U.S.A. 91, 12574-12578.
14. Chong, Z. Z., Shang, Y. C., Zhang, L., Wang, S., and Maiese, K. (2010). Mammalian target of rapamycin: hitting the bull's-eye for neurological disorders. Oxid. Med. Cell. Longev. 3, 374-391.
15. Collier, T. J., Kanaan, N. M., and Kor-dower, J. H. (2011). Ageing as a primary risk factor for Parkinson's disease: evidence from studies of non-human primates. Nat. Rev. Neurosci. 12, 359-366.
16. Cookson, M. R. (2010). The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. Nat. Rev. Neurosci. 11, 791-797.
17. Cross, D. A., Alessi, D. R., Cohen, P., Andjelkovich, M., and Hemmings, B. A. (1995). Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378, 785-789.
18. Dauer, W., and Przedborski, S. (2003). Parkinson's disease: mechanisms and models. Neuron 39, 889-909.
19. Devine, M. J., Plun-Favreau, H., and Wood, N. W. (2011). Parkinson's disease and cancer: two wars, one front. Nat. Rev. Cancer 11, 812-823.
20. Dexter, D. T., Carter, C. J., Wells, F. R., Javoy-Agid, F., Agid, Y., Lees, A., Jen-ner, P., and Marsden, C. D. (1989). Basal lipid peroxidation in substan-tia nigra is increased in Parkinson's disease. J. Neurochem. 52, 381-389.
21. D'Mello, S. R., Galli, C., Ciotti, T., and Calissano, P. (1993). Induction of apoptosis in cerebellar granule neurons by low potassium: inhibition of death by insulin-like growth factor I and cAMP. Proc. Natl. Acad. Sci. U.S.A. 90, 10989-10993.
22. Domin, J., and Waterfield, M. D. (1997). Using structure to define the function of phosphoinositide 3-kinase family members. FEBS Lett. 410, 91-95.
23. Drolet, R. E., Sanders, J. M., and Kern, J. T. (2011). Leucine-rich repeat kinase 2 (LRRK2) cellular biology: a review of recent advances in identifying physiological substrates and cellular functions. J. Neurogenet. 25, 140-151.
24. Elbaz,A., and Moisan,F. (2008). Update in the epidemiology of Parkinson's disease. Curr. Opin. Neurol. 21, 454-460.
25. Elbaz,A., and Tranchant,C. (2007). Epi-demiologic studies of environmental exposures in Parkinson's disease. J. Neurol. Sci. 262, 37-44.
26. Embi, N., Rylatt, D. B., and Cohen, P. (1980). Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphory-lase kinase. Eur. J. Biochem. 107, 519-527.
27. English, J. M., Pearson, G., Baer, R., and Cobb, M. H. (1998). Identification of substrates and regulators of the mitogen-activated protein kinase ERK5 using chimeric protein kinases. J. Biol. Chem. 273, 3854-3860.
28. English, J. M., Vanderbilt, C. A., Xu, S., Marcus, S., and Cobb, M. H. (1995). Isolation of MEK5 and differential expression of alternatively spliced forms. J. Biol. Chem. 270, 28897-28902.
29. Fingar, D. C., and Blenis, J. (2004). Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 23, 3151-3171.
30. Floor, E., and Wetzel, M. G. (1998). Increased protein oxidation in human substantia nigra pars com-pacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenyl-hydrazine assay. J. Neurochem. 70, 268-275.
31. Franklin, J. L., and Johnson, E. M. Jr. (1992). Suppression of programmed neuronal death by sustained elevation of cytoplasmic calcium. Trends Neurosci. 15, 501-508.
32. Fu, W. Y., Wang, J. H., and Ip, N. Y. (2002). Expression of Cdk5 and its activators in NT2 cells during neu-ronal differentiation. J. Neurochem. 81, 646-654.
33. Gao, C., Negash, S., Wang, H. S., Ledee, D., Guo, H., Russell, P., and Zelenka, P. (2001). Cdk5 mediates changes in morphology and promotes apopto-sis of astrocytoma cells in response to heat shock. J. Cell Sci. 114(Pt 6), 1145-1153.
34. Geisler, S., Holmström, K. M., Skujat, D., Fiesel, F. C., Rothfuss, O. C., Kahle, P. J., and Springer, W. (2010). PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. Nat. Cell Biol. 12, 119-131.
35. Ghosh, A., and Greenberg, M. E. (1995). Calcium signaling in neurons: molecular mechanisms and cellular consequences. Science 268, 239-247.
36. Gomez-Suaga, P., Luzon-Toro, B., Chu-ramani, D., Zhang, L., Bloor-Young, D., Patel, S., Woodman, P. G., Churchill, G. C., and Hilfiker, S. (2012). Leucine-rich repeat kinase 2 regulates autophagy through a calcium-dependent pathway involving NAADP. Hum. Mol. Genet. 21, 511-525.
37. Gong, X., Tang, X., Wiedmann, M., Wang, X., Peng, J., Zheng, D., Blair, L. A., Marshall, J., and Mao, Z. (2003). Cdk5-mediated inhibition of the protective effects of transcription factor MEF2 in neurotoxicity-induced apoptosis. Neuron 38, 33-46.
38. Grant, P., Sharma, P., and Pant, H. C. (2001). Cyclin-dependent protein kinase 5 (Cdk5) and the regulation of neurofilament metabolism. Eur. J. Biochem. 268, 1534-1546.
39. Graves, J. D., Draves, K. E., Craxton, A., Saklatvala, J., Krebs, E. G., and Clark, E. A. (1996). Involvement of stress-activated protein kinase and p38 mitogen-activated protein kinase in mIgM-induced apoptosis of human B lymphocytes. Proc. Natl. Acad. Sci. U.S.A. 93, 13814-13818.
40. Han, J., Jiang, Y., Li, Z., Kravchenko, V. V., and Ulevitch, R. J. (1997). Activation of the transcription factor MEF2C by the MAP kinase p38 in inflammation. Nature 386, 296-299.
41. Han, J., Lee, J. D., Bibbs, L., and Ulevitch, R. J. (1994). A MAP kinase targeted by endotoxin and hyperos-molarity in mammalian cells. Science 265, 808-811.
42. Han, J., Lee, J. D., Tobias, P. S., and Ulevitch, R. J. (1993). Endo-toxin induces rapid protein tyro-sine phosphorylation in 70Z/3 cells expressing CD14. J. Biol. Chem. 268, 25009-25014.
43. Hara, K., Maruki, Y., Long, X., Yoshino, K., Oshiro, N., Hidayat, S., Toku-naga, C., Avruch, J., and Yonezawa, K. (2002). Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 110, 177-189.
44. Hay, N., and Sonenberg, N. (2004). Upstream and downstream of mTOR. Genes Dev. 18, 1926-1945.
45. Hayashi, M., Fearns, C., Eliceiri, B., Yang, Y., and Lee, J. D. (2005). Big mitogen-activated protein kinase 1/extracellular signal-regulated kinase 5 signaling pathway is essential for tumor-associated angiogenesis. Cancer Res. 65, 7699-7706.
46. Healy, D. G., Falchi, M., O'Sullivan, S. S., Bonifati, V., Durr, A., Bress-man, S., Brice, A., Aasly, J., Zabetian, C. P., Goldwurm, S., Ferreira, J. J., Tolosa, E., Kay, D. M., Klein, C., Williams, D. R., Marras, C., Lang, A. E., Wszolek, Z. K., Berciano, J., Schapira, A. H., Lynch, T., Bhatia, K. P., Gasser, T., Lees, A. J., Wood, N. W., International LRRK2 Consortium. (2008). Phenotype, genotype, and worldwide genetic pene-trance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol. 7, 583-590.
47. Hellmich, M. R., Pant, H. C., Wada, E., and Battey, J. F. (1992). Neuronal cdc2-like kinase: a cdc2-related protein kinase with predominantly neu-ronal expression. Proc. Natl. Acad. Sci. U.S.A. 89, 10867-10871.
48. Hetman, M., Cavanaugh, J. E., Kimel-man, D., and Xia, Z. (2000). Role of glycogen synthase kinase-3beta in neuronal apoptosis induced by trophic withdrawal. J. Neurosci. 20, 2567-2574.
49. Hresko, R. C., and Mueckler, M. (2005). mTOR.RICTORisthe Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J. Biol. Chem. 280, 40406-40416.
50. Hughes, K., Nikolakaki, E., Plyte, S. E., Totty, N. F., and Woodgett, J. R. (1993). Modulation of the glycogen synthase kinase-3 family by tyro-sine phosphorylation. EMBO J. 12, 803-808.
51. Jacinto, E., Loewith, R., Schmidt, A., Lin, S., Rüegg, M. A., Hall, A., and Hall, M. N. (2004). Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat. Cell Biol. 6, 1122-1128.
52. Jiang, Y., Gram, H., Zhao, M., New, L., Gu, J., Feng, L., Di Padova, F., Ule-vitch, R. J., and Han, J. (1997). Characterization of the structure and function of the fourth member of p38 group mitogen-activated protein kinases, p38delta. J. Biol. Chem. 272, 30122-30128.
53. Jung, C. H., Ro, S. H., Cao, J., Otto, N. M., and Kim, D. H. (2010). mTOR regulation of autophagy. FEBS Lett. 584, 1287-1295.
54. Kalinderi, K., Fidani, L., Katsarou, Z., Clarimon, J., Bostantjopoulou, S., and Kotsis, A. (2011). GSK3beta polymorphisms, MAPT H1 haplotype and Parkinson's disease in a Greek cohort. Neurobiol. Aging 32, 546.e1-546.e5.
55. Kamakura, S., Moriguchi, T., and Nishida, E. (1999). Activation of the protein kinase ERK5/BMK1 by receptor tyrosine kinases. Identification and characterization of a signaling pathway to the nucleus. J. Biol. Chem. 274, 26563-26571.
56. Kato, Y., Kravchenko, V. V., Tapping, R. I., Han, J., Ulevitch, R. J., and Lee, J. D. (1997). BMK1/ERK5 regulates serum-induced early gene expression through transcription factor MEF2C. EMBO J. 16, 7054-7066.
57. Kato, Y., Tapping, R. I., Huang, S., Watson, M. H., Ulevitch, R. J., and Lee, J. D. (1998). Bmk1/Erk5 is required for cell proliferation induced by epidermal growth factor. Nature 395, 713-716.
58. Kaytor, M. D., and Orr, H. T. (2002). The GSK3 beta signaling cascade and neurodegenerative disease. Curr. Opin. Neurobiol. 12, 275-278.
59. Kim, D. H., Sarbassov, D. D., Ali, S. M., King, J. E., Latek, R. R., Erdjument-Bromage, H., Tempst, P., and Saba-tini, D. M. (2002). mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110, 163-175.
60. Kim, E. K., and Choi, E. J. (2010). Pathological roles of MAPK signaling pathways in human diseases. Biochim. Biophys. Acta 1802, 396-405.
61. Ko, J., Humbert, S., Bronson, R. T., Takahashi, S., Kulkarni, A. B., Li, E., and Tsai, L. H. (2001). p35 and p39 are essential for cyclin-dependent kinase 5 function during neurodevelopment. J. Neurosci. 21, 6758-6771.
62. Koh, P.-O. (2008). Melatonin prevents ischemic brain injury through activation of the mTOR/p70S6 kinase signaling pathway. Neurosci. Lett. 444, 74-78.
63. Koh, P.-O., Cho, J.-H., Won, C.-K., Lee, H.-J., Sung, J.-H., and Kim, M.-O. (2008). Estradiol attenuates the focal cerebral ischemic injury through mTOR/p70S6 kinase signaling pathway. Neurosci. Lett. 436, 62-66.
64. Kunz, J., Henriquez, R., Schneider, U., Deuter-Reinhard, M., Movva, N. R., and Hall, M. N. (1993). Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression. Cell 73, 585-596.
65. Kwok, J. B., Hallupp, M., Loy, C. T., Chan, D. K., Woo, J., Mellick, G. D., Buchanan, D. D., Silburn, P. A., Halliday, G. M., and Schofield, P. R. (2005). GSK3B polymorphisms alter transcription and splicing in Parkinson's disease. Ann. Neurol. 58, 829-839.
66. Lagace, D. C., Benavides, D. R., Kansy, J. W., Mapelli, M., Greengard, P., Bibb, J. A., and Eisch, A. J. (2008). Cdk5 is essential for adult hippocampal neurogenesis. Proc. Natl. Acad. Sci. U.S.A. 105, 18567-18571.
67. Lee, J. D., Ulevitch, R. J., and Han, J. (1995). Primary structure of BMK1: a new mammalian map kinase. Biochem. Biophys. Res. Commun. 213, 715-724.
68. Lees, A. J., Hardy, J., and Revesz, T. (2009). Parkinson's disease. Lancet 373, 2055-2066.
69. Leifer, D., Krainc, D., Yu, Y. T., McDer-mott, J., Breitbart, R. E., Heng, J., Neve, R. L., Kosofsky, B., Nadal-Ginard, B., and Lipton, S. A. (1993). MEF2C, a MADS/MEF2-family transcription factor expressed in a laminar distribution in cerebral cortex. Proc. Natl. Acad. Sci. U.S.A. 90, 1546-1550.
70. Lew, J., Huang, Q. Q., Qi, Z., Winkfein, R. J., Aebersold, R., Hunt, T., and Wang, J. H. (1994). A brain-specific activator of cyclin-dependent kinase 5. Nature 371, 423-426.
71. Lew, J.,Winkfein, R. J., Paudel, H. K.,and Wang, J. H. (1992). Brain proline-directed protein kinase is a neuro-filament kinase which displays high sequence homology to p34cdc2. J. Biol. Chem. 267, 25922-25926.
72. Li,Z., Jiang,Y., Ulevitch, R. J., and Han, J. (1996). The primary structure of p38 gamma: a new member of p38 group of MAP kinases. Biochem. Biophys. Res. Commun. 228, 334-340.
73. Lin, X., Parisiadou, L., Gu, X.-L., Wang, L., Shim, H., Sun, L., Xie, C., Long, C.-X., Yang, W.-J., Ding, J., Chen, Z. Z., Gallant, P. E., Tao-Cheng, J. H., Rudow, G., Troncoso, J. C., Liu, Z., Li, Z., and Cai, H. (2009). Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant α-synuclein. Neuron 64, 807-827.
74. Liu, L., Cavanaugh, J. E., Wang, Y., Sakagami, H., Mao, Z., and Xia, Z. (2003). ERK5 activation of MEF2-mediated gene expression plays a critical role in BDNF-promoted survival of developing but not mature cortical neurons. Proc. Natl. Acad. Sci. U.S.A. 100, 8532-8537.
75. Lucas, J. J., Hernandez, F., Gomez-Ramos, P., Moran, M. A., Hen, R., and Avila, J. (2001). Decreased nuclear beta-catenin, tau hyper-phosphorylation and neurodegen-eration in GSK-3beta conditional transgenic mice. EMBO J. 20, 27-39.
76. MacLeod, D., Dowman, J., Hammond, R., Leete, T., Inoue, K., and Abe-liovich, A. (2006). The familial parkinsonism gene LRRK2 regulates neurite process morphology. Neuron 52, 587-593.
77. Mao, Z., Bonni,A., Xia, F., Nadal-Vicens, M., and Greenberg, M. E. (1999). Neuronal activity-dependent cell survival mediated by transcription factor MEF2. Science 286, 785-790.
78. Marinissen, M. J., Chiariello, M., Pal-lante, M., and Gutkind, J. S. (1999). A network of mitogen-activated protein kinases links G protein-coupled receptors to the c-jun promoter: a role for c-Jun NH2-terminal kinase, p38s, and extracellular signal-regulated kinase 5. Mol. Cell. Biol. 19, 4289-4301.
79. Matsuda, N., Sato, S., Shiba, K., Okatsu, K., Saisho, K., Gautier, C. A., Sou, Y. S., Saiki, S., Kawajiri, S., Sato, F., Kimura, M., Komatsu, M., Hattori, N., and Tanaka, K. (2010). PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy. J. Cell Biol. 189, 211-221.
80. Mertens, S., Craxton, M., and Goedert, M. (1996). SAP kinase-3, a new member of the family of mammalian stress-activated protein kinases. FEBS Lett. 383, 273-276.
81. Meyerson, M., Enders, G. H., Wu, C. L., Su, L. K., Gorka, C., Nelson, C., Har-low, E., and Tsai,L. H. (1992).A family of human cdc2-related protein kinases. EMBO J. 11, 2909-2917.
82. Miller, T. M., Tansey, M. G., Johnson, E. M. Jr., and Creedon, D. J. (1997). Inhibition of phos-phatidylinositol 3-kinase activity blocks depolarization- and insulinlike growth factor I-mediated survival of cerebellar granule cells. J. Biol. Chem. 272, 9847-9853.
83. Mora, A., Sabio, G., Gonzalez-Polo, R. A., Cuenda, A., Alessi, D. R., Alonso, J. C., Fuentes, J. M., Soler, G., and Centeno, F. (2001). Lithium inhibits caspase 3 activation and dephospho-rylation of PKB and GSK3 induced by K+ deprivation in cerebellar granule cells. J. Neurochem. 78, 199-206.
84. Narendra, D., Tanaka, A., Suen, D. F., and Youle, R. J. (2008). Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J. Cell Biol. 183, 795-803.
85. Narendra, D. P., Jin, S. M., Tanaka, A., Suen, D.-F., Gautier, C. A., Shen, J., Cookson, M. R., and Youle, R. J. (2010). PINK1 is selectively stabilized on impaired mitochondria to activate parkin. PLoS Biol. 8, e1000298. doi:10.1371/journal.pbio.1000298
86. Newhouse, K., Hsuan, S. L., Chang, S. H., Cai, B., Wang, Y., and Xia, Z. (2004). Rotenone-induced apopto-sis is mediated by p38 and JNK MAP kinases in human dopamin-ergic SH-SY5Y cells. Toxicol. Sci. 79, 137-146.
87. Ohshima, T., Ward, J. M., Huh, C. G., Longenecker, G., Veeranna, Pant, H. C., Brady, R. O., Martin, L. J., and Kulkarni, A. B. (1996). Targeted disruption of the cyclin-dependent kinase 5 gene results in abnormal corticogenesis, neuronal pathology and perinatal death. Proc. Natl. Acad. Sci. U.S.A. 93, 11173-11178.
88. Okamoto, S., Krainc, D., Sherman, K., and Lipton, S. A. (2000). Anti-apoptotic role of the p38 mitogen-activated protein kinase-myocyte enhancer factor 2 transcription factor pathway during neuronal differentiation. Proc. Natl. Acad. Sci. U.S.A. 97, 7561-7566.
89. Oppenheim, R. W. (1991). Cell death during development of the nervous system. Annu. Rev. Neurosci. 14, 453-501.
90. Paisán-Ruíz, C., Jain, S., Evans, E. W., Gilks, W. P., Simón, J., Van der Brug, M., de Munain, A. L., Aparicio, S., Gil, A. M. N., Khan, N., Johnson, J., Martinez, J. R., Nicholl, D., Carrera, I. M., Pena, A. S., de Silva, R., Lees, A., Martí-Massó, J. F., Pérez-Tur, J., Wood, N. W., and Singleton, A. B. (2004). Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44, 595-600.
91. Pap, M., and Cooper, G. M. (1998). Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-kinase/Akt cell survival pathway. J. Biol. Chem. 273, 19929-19932.
92. Patrick, G. N., Zukerberg, L., Nikolic, M., De la Monte, S., Dikkes, P., and Tsai, L. H. (1999). Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 402, 615-622.
93. Pattingre, S., Espert, L., Biard-Piechaczyk, M., and Codogno, P. (2008). Regulation of macroau-tophagy by mTOR and Beclin 1 complexes. Biochimie 90, 313-323.
94. Pearce, R. K., Owen, A., Daniel, S., Jen-ner, P., and Marsden, C. D. (1997). Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease. J. Neural Transm. 104, 661-677.
95. Plowey, E. D., Cherra, S. J. III, Liu, Y. J., and Chu, C. T. (2008). Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells. J. Neu-rochem. 105, 1048-1056.
96. Raingeaud, J., Gupta, S., Rogers, J. S., Dickens, M., Han, J., Ulevitch, R. J., and Davis, R. J. (1995). Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine. J. Biol. Chem. 270, 7420-7426.
97. Ramonet, D., Daher, J. P., Lin, B. M., Stafa, K., Kim, J., Banerjee, R., West-erlund, M., Pletnikova, O., Glauser, L., Yang, L., Liu, Y., Swing, D. A., Beal, M. F., Troncoso, J. C., McCaffery, J. M., Jenkins, N. A., Copeland, N. G., Galter, D., Thomas, B., Lee, M. K., Dawson, T. M., Dawson, V. L., and Moore, D. J. (2011). Dopamin-ergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. PLoS ONE 6, e18568. doi:10.1371/jour-nal.pone.0018568
98. Rampalli, S., Li, L., Mak, E., Ge, K., Brand, M., Tapscott, S. J., and Dil-worth, F. J. (2007). p38 MAPK signaling regulates recruitment of Ash2L-containing methyltransferase complexes to specific genes during differentiation. Nat. Struct. Mol. Biol. 14, 1150-1156.
99. Roberts, O. L., Holmes, K., Müller, J., Cross, D. A., and Cross, M. J. (2009). ERK5 and the regulation of endothelial cell function. Biochem. Soc. Trans. 37, 1254.
100. Rydel, R. E., and Greene, L. A. (1988). cAMP analogs promote survival and neurite outgrowth in cultures of rat sympathetic and sensory neurons independently of nerve growth factor. Proc. Natl. Acad. Sci. U.S.A. 85, 1257-1261.
101. Rylatt, D. B.,Aitken, A., Bilham, T., Condon, G. D., Embi, N., and Cohen, P. (1980). Glycogen synthase from rabbit skeletal muscle. Amino acid sequence at the sites phosphorylated by glycogen synthase kinase-3, and extension of the N-terminal sequence containing the site phos-phorylated by phosphorylase kinase. Eur. J. Biochem. 107, 529-537.
102. Sabatini, D. M., Erdjument-Bromage, H., Lui, M., Tempst, P., and Snyder, S. H. (1994). RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 78, 35-43.
103. Sarbassov, D. D., Ali, S. M., Kim, D. H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., Tempst, P., and Sabatini, D. M. (2004). Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol. 14, 1296-1302.
104. Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., and Sabatini, D. M. (2006). Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 22, 159-168.
105. Sato, S., and Hattori, N. (2011). Genetic mutations and mitochondrial toxins shed new light on the pathogene-sis of Parkinson's disease. Parkinsons Dis. 2011, 1-7.
106. Segal, R. A., and Greenberg, M. E. (1996). Intracellular signaling pathways activated by neurotrophic factors. Annu. Rev. Neurosci. 19, 463-489.
107. Seki, N., Takahashi, Y., Tomiyama, H., Rogaeva, E., Murayama, S., Mizuno, Y., Hattori, N., Marras, C., Lang, A. E., George-Hyslop, P. S., Goto, J., and Tsuji, S. (2011). Comprehensive mutational analysis of LRRK2 reveals variants supporting association with autosomal dominant Parkinson's disease. J. Hum. Genet. 56, 671-675.
108. Shalizi, A., Lehtinen, M., Gaudilliere, B., Donovan,N., Han, J.,Konishi,Y.,and Bonni, A. (2003). Characterization of a neurotrophin signaling mechanism that mediates neuron survival in a temporally specific pattern. J. Neurosci. 23, 7326-7336.
109. Sharma, P., Sharma, M., Amin, N. D., Albers, R. W., and Pant, H. C. (1999). Regulation of cyclin-dependent kinase 5 catalytic activity by phosphorylation. Proc. Natl. Acad. Sci. U.S.A. 96, 11156-11160.
110. She, H., Yang, Q., Shepherd, K., Smith, Y., Miller, G., Testa, C., and Mao, Z. (2011). Direct regulation of complex I by mitochondrial MEF2D is disrupted in a mouse model of Parkinson disease and in human patients. J. Clin. Invest. 121, 930-940.
111. Sherer, T. B., Betarbet, R., Testa, C. M., Seo, B. B., Richardson, J. R., Kim, J. H., Miller, G. W., Yagi, T., Matsuno-Yagi, A., and Greenamyre, J. T. (2003). Mechanism of toxicity in rotenone models of Parkinson's disease. J. Neurosci. 23, 10756-10764.
112. Smith, D. S., Greer, P. L., and Tsai, L. H. (2001). Cdk5 on the brain. Cell Growth Differ. 12, 277-283.
113. Smith, P. D., Mount, M. P., Shree, R., Callaghan, S., Slack, R. S., Anisman, H., Vincent, I., Wang, X., Mao, Z., and Park, D. S. (2006). Calpain-regulated p35/cdk5 plays a central role in dopaminergic neuron death through modulation of the transcription factor myocyte enhancer factor 2. J. Neurosci. 26, 440-447.
114. Spillantini, M. G., Schmidt, M. L., Lee, V. M., Trojanowski, J. Q., Jakes, R., and Goedert, M. (1997). Alpha-synuclein in Lewy bodies. Nature 388, 839-840.
115. Suzaki, Y., Yoshizumi, M., Kagami, S., Koyama,A. H., Taketani, Y., Houchi, H., Tsuchiya, K., Takeda, E., and Tamaki, T. (2002). Hydrogen peroxide stimulates c-Src-mediated big mitogen-activated protein kinase 1 (BMK1) and the MEF2C signaling pathway in PC12 cells: potential role in cell survival following oxidative insults. J. Biol. Chem. 277, 9614-9621.
116. Tanaka, T., Veeranna, Ohshima, T., Rajan, P., Amin, N. D., Cho, A., Sreenath, T., Pant, H. C., Brady, R. O., and Kulkarni,A. B. (2001). Neuronal cyclin-dependent kinase 5 activity is critical for survival. J. Neurosci. 21, 550-558.
117. Tang, D., Yeung, J., Lee, K. Y., Matsushita, M., Matsui, H., Tomizawa, K., Hatase, O., and Wang, J. H. (1995). An isoform of the neuronal cyclin-dependent kinase 5 (Cdk5) activator. J. Biol. Chem. 270, 26897-26903.
118. Tang, X., Wang, X., Gong, X., Tong, M., Park, D., Xia, Z., and Mao, Z. (2005). Cyclin-dependent kinase 5 mediates neurotoxin-induced degradation of the transcription factor myocyte enhancer factor 2. J. Neurosci. 25, 4823-4834.
119. Tanner, C. M., and Aston, D. A. (2000). Epidemiology of Parkinson's disease and akinetic syndromes. Curr. Opin. Neurol. 13, 427-430.
120. Thacker, E. L., Chen, H., Patel, A. V., McCullough, M. L., Calle, E. E., Thun, M. J., Schwarzschild, M. A., and Ascherio, A. (2008). Recreational physical activity and risk of Parkinson's disease. Mov. Disord. 23, 69-74.
121. Tsai, L. H., Delalle, I., Caviness, V. S. Jr., Chae, T., and Harlow, E. (1994). p35 is a neural-specific regulatory sub-unit of cyclin-dependent kinase 5. Nature 371, 419-423.
122. Tsai, L. H., Takahashi, T., Caviness, V. S. Jr., and Harlow, E. (1993). Activity and expression pattern of cyclin-dependent kinase 5 in the embryonic mouse nervous system. Development 119, 1029-1040.
123. Tung, H. Y., and Reed, L. J. (1989). Purification and characterization of protein phosphatase 1I activating kinase from bovine brain cytoso-lic and particulate fractions. J. Biol. Chem. 264, 2985-2990.
124. Unoki, M., and Nakamura, Y. (2001). Growth-suppressive effects of BPOZ and EGR2, two genes involved in the PTEN signaling pathway. Oncogene 20, 4457-4465.
125. Valente, E. M., Abou-Sleiman, P. M., Caputo, V., Muqit, M. M., Harvey, K., Gispert, S., Ali, Z., Del Turco, D., Bentivoglio, A. R., Healy, D. G., Albanese, A., Nuss-baum, R., González-Maldonado, R., Deller, T., Salvi, S., Cortelli, P., Gilks, W. P., Latchman, D. S., Harvey, R. J., Dallapiccola, B., Auburger, G., and Wood, N. W. (2004). Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304, 1158-1160.
126. Vives-Bauza, C., Zhou, C., Huang, Y., Cui, M., De Vries, R. L. A., Kim, J., May, J., Tocilescu, M. A., Liu, W., Ko, H. S., Magrané, J., Moore, D. J., Dawson, V. L., Grailhe, R., Dawson, T. M., Li, C., Tieu, K., and Przed-borski, S. (2010). PINK1-dependent recruitment of Parkin to mitochondria in mitophagy. Proc. Natl. Acad. Sci. U.S.A. 107, 378-383.
127. Vogiatzi, T., Xilouri, M., Vekrellis, K., and Stefanis, L. (2008). Wild type alpha-synuclein is degraded by chaperone-mediated autophagy and macroautophagy in neuronal cells. J. Biol. Chem. 283, 23542-23556.
128. Wang, X., She, H., and Mao, Z. (2009). Phosphorylation of neuronal survival factor MEF2D by glycogen syn-thase kinase 3 in neuronal apoptosis. J. Biol. Chem. 284, 32619-32626.
129. Wang, X., Tang, X., Li, M., Marshall, J., and Mao, Z. (2005). Regulation of neuroprotective activity of myocyte-enhancer factor 2 by cAMP-protein kinase A signaling pathway in neu-ronal survival. J. Biol. Chem. 280, 16705-16713.
130. Wider, C., Dickson, D. W., and Wszolek, Z. K. (2010). Leucine-rich repeat kinase 2 gene-associated disease: redefining genotype-phenotype correlation. Neurodegener. Dis. 7, 175-179.
131. Williams, A., Jahreiss, L., Sarkar, S., Saiki, S., Menzies, F. M., Ravikumar, B., and Rubinsztein, D. C. (2006). Aggregate-prone proteins are cleared from the cytosol by autophagy: therapeutic implications. Curr. Top. Dev. Biol. 76, 89-101.
132. Woodgett, J. R. (1990). Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J. 9, 2431-2438.
133. Xia, Z., Dickens, M., Raingeaud, J., Davis, R. J., and Greenberg, M. E. (1995). Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270, 1326-1331.
134. Xiong, Y., Coombes, C. E., Kilaru, A., Li, X., Gitler, A. D., Bowers, W. J., Dawson, V. L., Dawson, T. M., and Moore, D. J. (2010). GTPase activity plays a key role in the pathobiology of LRRK2. PLoS Genet. 6, e1000902. doi:10.1371/journal.pgen.1000902
135. Xu, Q., and Wu, Z. (2000). The insulin-like growth factor-phosphatidylinositol 3-kinase-Akt signaling pathway regulates myogenin expression in normal myogenic cells but not in rhabdomyosarcoma-derived RD cells. J. Biol. Chem. 275, 36750-36757.
136. Yan, L., Carr, J., Ashby, P. R., Murry-Tait, V., Thompson, C., and Arthur, J. S. (2003). Knockout of ERK5 causes multiple defects in pla-cental and embryonic development. BMC Dev. Biol. 3, 11. doi:10.1186/1471-213X-3-11
137. Yang, C. C., Ornatsky, O. I., McDer-mott, J. C., Cruz, T. F., and Prody, C. A. (1998). Interaction of myocyte enhancer factor 2 (MEF2) with a mitogen-activated protein kinase, ERK5/BMK1. Nucleic Acids Res. 26, 4771-4777.
138. Yang, Q., She, H., Gearing, M., Colla, E., Lee, M., Shacka, J. J., and Mao, Z. (2009). Regulation of neuronal survival factor MEF2D by chaperone-mediated autophagy. Science 323, 124-127.
139. Yang, S. H., Galanis, A., and Shar-rocks, A. D. (1999). Targeting of p38 mitogen-activated protein kinases to MEF2 transcription factors. Mol. Cell. Biol. 19, 4028-4038.
140. Yu, Y. T., Breitbart, R. E., Smoot, L. B., Lee, Y., Mahdavi, V., and Nadal-Ginard, B. (1992). Human myocyte-specific enhancer factor 2 comprises a group of tissue-restricted MADS box transcription factors. Genes Dev. 6, 1783-1798.
141. Zhang, Q., Ahuja, H. S., Zakeri, Z. F., and Wolgemuth, D. J. (1997). Cyclin-dependent kinase 5 is associated with apoptotic cell death during development and tissue remodeling. Dev. Biol. 183, 222-233.
142. Zhao, M., New, L., Kravchenko, V. V., Kato, Y., Gram, H., di Padova, F., Olson, E. N., Ulevitch, R. J., and Han, J. (1999). Regulation of the MEF2 family of transcription factors by p38. Mol. Cell. Biol. 19, 21-30.
143. Zheng, M., Leung, C. L., and Liem, R. K. (1998). Region-specific expression of cyclin-dependent kinase 5 (cdk5) and its activators, p35 and p39, in the developing and adult rat central nervous system. J. Neurobiol. 35, 141-159.
144. Zhou, G., Bao, Z. Q., and Dixon, J. E. (1995). Components of a new human protein kinase signal transduction pathway. J. Biol. Chem. 270, 12665-12669.
145. Zhou, H., and Huang, S. (2010). The complexes of mammalian target of rapamycin. Curr. Protein Pept. Sci. 11, 409-424.
146. Zhu, J., Li, W., and Mao, Z. (2011). Cdk5: mediator of neuronal development, death and the response to DNA damage. Mech. Ageing Dev. 132, 389-394.
147. Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., Kachergus, J., Hulihan, M., Uitti, R. J., Calne, D. B., Stoessl, A. J., Pfeiffer, R. F., Patenge, N., Car-bajal, I. C., Vieregge, P., Asmus, F., Müller-Myhsok, B., Dickson, D. W., Meitinger, T., Strom, T. M., Wszolek, Z. K., and Gasser, T. (2004). Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44, 601-607.
148. Zukerberg, L. R., Patrick, G. N., Nikolic, M., Humbert, S., Wu, C. L., Lanier, L. M., Gertler, F. B., Vidal, M., Van Etten, R. A., and Tsai, L. H. (2000). Cables links Cdk5 and c-Abl and facilitates Cdk5 tyrosine phos-phorylation, kinase upregulation, and neurite outgrowth. Neuron 26, 633-646.